# A Study Conducted in Healthy Subjects to Demonstrate Bioequivalence Between Ropinirole Prolonged Release Tablets Manufactured at Crawley and Aranda

> **NCT01371682** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 50 (actual)

## Conditions studied

- Parkinson Disease

## Interventions

- **DRUG:** Ropinirole XL

## Key facts

- **NCT ID:** NCT01371682
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-09-18
- **Primary completion:** 2009-12-02
- **Final completion:** 2009-12-02
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2018-06-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01371682

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01371682, "A Study Conducted in Healthy Subjects to Demonstrate Bioequivalence Between Ropinirole Prolonged Release Tablets Manufactured at Crawley and Aranda". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01371682. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*